Literature DB >> 29020172

Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.

Tafese Beyene1,2, Anteneh G Zewde3, Abera Balcha4, Belda Hirpo1, Tadele Yitbarik5, Teshome Gebissa1, Radha Rajasingham3, David R Boulware3.   

Abstract

A total of 817 human immunodeficiency virus-infected Ethiopians with CD4 <150 cells/mL underwent plasma cryptococcal antigen (CRAG) screening. CRAG prevalence was 6.2%. Of participants with plasma CRAG titers >1:640, 96% (27 of 28) had cryptococcal meningitis (cerebrospinal fluid CRAG-positive) whereas 50% (7 of 14) with 1:160-1:320 titers had meningitis. With fluconazole 1200 mg/d therapy, 68% of meningitis patients (23 of 34) died within 3 months. Plasma CRAG titers >1:160 predict meningitis, requiring more intensive antifungal therapy.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cryptococcal meningitis /PC; Cryptococcosis /PC; Cryptococcus; Ethiopia; Fluconazole; Mass Screening; Prevention & Control

Mesh：

Substances：

Year:  2017        PMID： 29020172      PMCID： PMC5850618          DOI： 10.1093/cid/cix613

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  14 in total

1.  Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.

Authors:  David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

2.  Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial.

Authors:  Sayoki Mfinanga; Duncan Chanda; Sokoine L Kivuyo; Lorna Guinness; Christian Bottomley; Victoria Simms; Carol Chijoka; Ayubu Masasi; Godfather Kimaro; Bernard Ngowi; Amos Kahwa; Peter Mwaba; Thomas S Harrison; Saidi Egwaga; Shabbar Jaffar
Journal:  Lancet       Date:  2015-03-10       Impact factor: 79.321

3.  Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis.

Authors:  Radha Rajasingham; Melissa A Rolfes; Kate E Birkenkamp; David B Meya; David R Boulware
Journal:  PLoS Med       Date:  2012-09-25       Impact factor: 11.069

4.  Comparison of cryptococcal antigenemia between antiretroviral naïve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia.

Authors:  Tafese Beyene; Yimtubezinash Woldeamanuel; Daniel Asrat; Gonfa Ayana; David R Boulware
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

5.  Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes.

Authors:  Joseph N Jarvis; Tihana Bicanic; Angela Loyse; Daniel Namarika; Arthur Jackson; Jesse C Nussbaum; Nicky Longley; Conrad Muzoora; Jacob Phulusa; Kabanda Taseera; Creto Kanyembe; Douglas Wilson; Mina C Hosseinipour; Annemarie E Brouwer; Direk Limmathurotsakul; Nicholas White; Charles van der Horst; Robin Wood; Graeme Meintjes; John Bradley; Shabbar Jaffar; Thomas Harrison
Journal:  Clin Infect Dis       Date:  2013-12-06       Impact factor: 9.079

6.  Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.

Authors:  Nicky Longley; Conrad Muzoora; Kabanda Taseera; James Mwesigye; Joselyne Rwebembera; Ali Chakera; Emma Wall; Irene Andia; Shabbar Jaffar; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

7.  The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis.

Authors:  Melissa A Rolfes; Kathy Huppler Hullsiek; Joshua Rhein; Henry W Nabeta; Kabanda Taseera; Charlotte Schutz; Abdu Musubire; Radha Rajasingham; Darlisha A Williams; Friedrich Thienemann; Conrad Muzoora; Graeme Meintjes; David B Meya; David R Boulware
Journal:  Clin Infect Dis       Date:  2014-07-23       Impact factor: 9.079

8.  Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality.

Authors:  Emilio Letang; Matthias C Müller; Alex J Ntamatungiro; Namvua Kimera; Diana Faini; Hansjakob Furrer; Manuel Battegay; Marcel Tanner; Christoph Hatz; David R Boulware; Tracy R Glass
Journal:  Open Forum Infect Dis       Date:  2015-04-02       Impact factor: 3.835

9.  Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa.

Authors:  Joseph N Jarvis; Thomas S Harrison; Stephen D Lawn; Graeme Meintjes; Robin Wood; Susan Cleary
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

10.  Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.

Authors:  Nicky Longley; Joseph Nicholas Jarvis; Graeme Meintjes; Andrew Boulle; Anna Cross; Nicola Kelly; Nelesh P Govender; Linda-Gail Bekker; Robin Wood; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2015-11-12       Impact factor: 9.079
View more
  32 in total

1.  Cryptococcal Antigen Screening and Preemptive Treatment-How Can We Improve Survival?

Authors:  Radha Rajasingham; David R Boulware
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

2.  Global HIV neurology: a comprehensive review.

Authors:  Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

3.  A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda.

Authors:  Elizabeth Nalintya; David B Meya; Sarah Lofgren; Kathy Huppler Hullsiek; David R Boulware; Radha Rajasingham
Journal:  J Acquir Immune Defic Syndr       Date:  2018-06-01       Impact factor: 3.731

4.  Cryptococcal and Histoplasma Antigen Screening Among People With Human Immunodeficiency Virus in Ghana and Comparative Analysis of OIDx Histoplasma Lateral Flow Assay and IMMY Histoplasma Enzyme Immunoassay.

Authors:  Bright K Ocansey; Benjamin Otoo; Isabella Asamoah; Vincent Ganu; Kofi P Berko; Oluwakemi Oladele; Emmanuella A Amankwa; Bismark Opoku-Asare; Martin Agyei; Lawrence George; Fleischer C N Kotey; Chris Kosmidis; Peter Puplampu; Japheth A Opintan; David W Denning
Journal:  Open Forum Infect Dis       Date:  2022-06-03       Impact factor: 4.423

Review 5.  Neurologic Complications of Human Immunodeficiency Virus Infection.

Authors:  Deanna Saylor
Journal:  Continuum (Minneap Minn)       Date:  2018-10

Review 6.  Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing.

Authors:  Radha Rajasingham; Rachel M Wake; Tafese Beyene; Andrew Katende; Emilio Letang; David R Boulware
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

7.  Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis.

Authors:  Kenneth Ssebambulidde; Ananta S Bangdiwala; Richard Kwizera; Tadeo Kiiza Kandole; Lillian Tugume; Reuben Kiggundu; Edward Mpoza; Edwin Nuwagira; Darlisha A Williams; Sarah M Lofgren; Mahsa Abassi; Abdu K Musubire; Fiona V Cresswell; Joshua Rhein; Conrad Muzoora; Kathy Huppler Hullsiek; David R Boulware; David B Meya
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

8.  Should we perform the serum cryptococcal antigen test in people living with HIV hospitalized due to a community-acquired pneumonia episode?

Authors:  Adriana Paulino Silva; Carolina Toniolo Zenatti; Claudia Figueiredo-Mello; Marinella Della Negra; Anna S Levin; David R Boulware; José Ernesto Vidal
Journal:  Int J STD AIDS       Date:  2020-02-23       Impact factor: 1.359

Review 9.  New Insights Into Cryptococcus Spp. Biology and Cryptococcal Meningitis.

Authors:  Elvis Temfack; Timothée Boyer-Chammard; David Lawrence; Sarah Delliere; Angela Loyse; Fanny Lanternier; Alexandre Alanio; Olivier Lortholary
Journal:  Curr Neurol Neurosci Rep       Date:  2019-10-31       Impact factor: 5.081

10.  Evaluation of the Diagnostic Performance of a Semiquantitative Cryptococcal Antigen Point-of-Care Assay among HIV-Infected Persons with Cryptococcal Meningitis.

Authors:  David R Boulware; Caleb P Skipper; Kiiza Kandole Tadeo; Audrey Nimwesiga; Richard Kwizera; Lucy Apeduno; Emily Martyn; Michael Okirwoth; Elizabeth Nalintya; Radha Rajasingham; Darlisha A Williams; Joshua Rhein; David B Meya; Bosco Kafufu
Journal:  J Clin Microbiol       Date:  2021-07-19       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.